Author

Ehud Marom

Observed names: E. Marom, EHUD MAROM

Observed institution: Mapi Pharma (Israel)

OpenAlex ID: A5002755087

Exosomes derived from adipose mesenchymal stem cells: a potential non-invasive intranasal treatment for autism

2020 · Y. Geffen, N. Perets, et al. · Cytotherapy · 17

Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders

2021 · Karin Mausner-Fainberg, Moshe Benhamou, et al. · Neurotherapeutics · 7

PDF

Immuno-Modulation and neuroprotection mediate the therapeutic effect of exosomes in mice model of autism

2020 · Y. Geffen, R. Horev, et al. · Cytotherapy · 5

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911)

2021 · Shlomo Flechter, Laura Popper, et al. · Neurology · 2

Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359)

2018 · Ariel Miller, Laura Popper, et al. · Neurology · 2

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)

2024 · Aaron Miller, Laura Popper, et al. · Neurology · 1

GA Depot (Long-acting IM Glatiramer Acetate) and its Impact on EDSS in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P7-19.002)

2026 · Aaron Miller, Laura Popper, et al. · Neurology

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial

2026 · Aaron Miller, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal

PDF

1689-P: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling

2025 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Impact on EDSS Stability in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P11-1.014)

2025 · Aaron Miller, Laura Popper, et al. · Neurology

Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd

2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Gastroenterology

Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd

2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Inflammatory Bowel Diseases

2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration

2024 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes

Oral Administration of a Novel Small Molecule Blocks the BMP Canonical and the Non-canonical BMP2, BMP4, and BMP5 Signaling Pathways Ameliorates EAE Through Oligodendrogenesis Remyelination and Preservation of Axonal Integrity and Reduces Astrogenesis (P7-6.015)

2024 · Maya Golan, Moshe Benhamou, et al. · Neurology

Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)

2023 · Aaron Miller, Laura Popper, et al. · Neurology

Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001)

2022 · Shlomo Flechter, Laura Popper, et al. · Neurology

Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010)

2022 · Shlomo Flechter, Ariel Miller, et al. · Neurology

Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders (2042)

2021 · Karin Fainberg-Mausner, Moshe Benhamou, et al. · Neurology

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot (1956)

2020 · Shlomo Flechter, Laura Popper, et al. · Neurology

Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation three-years analysis (1936)

2020 · Shlomo Flechter, Ariel Miller, et al. · Neurology

Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis (P3.2-052)

2019 · Shlomo Flechter, Ariel Miller, et al. · Neurology

Synergistic effect of human adipose derived mesenchymal cells (ADSC) and glatiramer acetate long acting injection (GA depot) on MOG-induced chronic eae in C57bl/6 mice

2018 · F. Grynspan, N. Bleich Kimelman, et al. · Cytotherapy

Pre-Clinical Studies and Evaluation of Treatment Need of Glatiramer Acetate Depot (Long Acting Injection) (P5.314)

2016 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Neurology

Works count: 23

Citation count: 34

H-index: 3

I10-index: 1